-
A NEW ERA
IN
GENE THERAPY
-
A NEW ERA
IN
GENE THERAPY
We are pioneering non-viral gene therapies for mucosal tissues
enGene has developed a solution to the long-standing challenge of producing gene therapies that can be dosed orally and can penetrate mucosal tissues. Our Dually Derivitized Oligochitosan (DDX®) formulation is optimized to package and transport DNA into epithelial cells situated behind mucus barriers. Coupling this pioneering technology to our deep scientific know-how and dedicated team, we are passionately focused on making our vision a reality — creating simple and effective gene therapies for a healthier and higher quality of life.
We are pioneering non-viral gene therapies for mucosal tissues
enGene has developed a solution to the long-standing challenge of producing gene therapies that can be dosed orally and can penetrate mucosal tissues. Our Dually Derivitized Oligochitosan (DDX®) formulation is optimized to package and transport DNA into epithelial cells situated behind mucus barriers. Coupling this pioneering technology to our deep scientific know-how and dedicated team, we are passionately focused on making our vision a reality — creating simple and effective gene therapies for a healthier and higher quality of life.
-
enGene Announces Additions
to Senior Management TeamJanuary 8th, 2020 -
enGene Appoints José M. Lora, PhD
as Chief Scientific OfficerMay 29th, 2019 -
enGene Appoints Veteran Life Sciences
Executive Jason D. Hanson as
Chief Executive Officer and PresidentJuly 16th, 2018 -
Industry Veteran Mr. Steve Gannon Joins
enGene’s Board of DirectorsJuly 10, 2017
